All studies
Active not recruitingPHASE2INTERVENTIONAL

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis is a long-term condition that causes inflammation and sores in the lining of the large bowel. While treatments are available, they do not work for everyone, leaving many people with ongoing stomach pain, frequent toilet visits, and bleeding. This Phase 2 trial is investigating a new medicine called emvistegrast (previously known as GS-1427). The main aim is to find out if emvistegrast is safe and effective in calming bowel inflammation in adults with moderate to severe ulcerative colitis. Participants will be placed into groups by chance to receive either emvistegrast or an inactive dummy treatment (placebo). Doctors will closely check their bowel symptoms, overall health, and gut healing over 12 weeks to see whether the new medicine provides clear benefits compared to the placebo.

At a glance

Status
Active not recruiting
Phase
PHASE2
Sponsor
Gilead Sciences
Enrolment target
228
Start
27 Mar 2024
Estimated completion
01 Apr 2028

What is this study about?

Ulcerative colitis is a chronic illness where parts of the large bowel become swollen and irritated. Living with an active flare-up can be difficult and exhausting, often causing frequent diarrhoea, stomach cramps, and extreme tiredness. While many people find relief with existing medications, these treatments can lose their effect over time or cause unwanted side effects. Finding new and better ways to control inflammation is essential.

This clinical trial is studying an experimental medicine called emvistegrast. Emvistegrast works by targeting specific proteins involved in the body's immune response, aiming to stop inflammation-causing cells from traveling into the bowel tissue. By calming this immune activity, researchers hope the medicine will help heal the lining of the bowel and relieve symptoms.

In this Phase 2 study, doctors are comparing emvistegrast to a placebo, which looks identical but contains no active drug. Comparing the two helps researchers prove whether any improvements in health are genuinely caused by the new medicine. The main results will be measured after 12 weeks of treatment to see if patients achieve a meaningful improvement in their symptoms and bowel inflammation.

Key takeaways

  • The study tests a new medicine called emvistegrast for moderate to severe ulcerative colitis.
  • It is open to adults aged 18 to 75 whose previous colitis treatments did not work well enough.
  • Participants will receive either the study medicine or a dummy treatment (placebo).
  • Doctors will measure improvements in symptoms and bowel healing after 12 weeks.
  • Joining is entirely voluntary, and you can withdraw at any time without affecting your NHS care.

Who may be eligible?

This trial is designed for adults aged between 18 and 75 who have had ulcerative colitis symptoms for at least three months. To take part, your diagnosis must be confirmed by past camera tests of the bowel (endoscopy) and tissue samples. Your colitis must also be currently moderately to severely active, affecting at least 15 centimetres of the lower bowel.

The study is meant for people whose condition has not improved enough with standard treatments, such as steroids, immune-suppressing medicines, or targeted biologic therapies, or who could not tolerate them due to side effects. However, you cannot join if you have already tried three or more different types of advanced biologic therapies.

People with other types of bowel conditions, such as Crohn's disease, cannot take part. You will also be excluded if you have had serious bowel complications (like toxic megacolon or severe blockages) or if you have previously taken specific gut-targeted medicines called integrin blockers, such as vedolizumab.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. You are between 18 and 75 years of age.
  2. You have had diagnosed ulcerative colitis symptoms for at least 90 days.
  3. Your colitis is currently moderately to severely active.
  4. Previous colitis treatments (like steroids or biologics) did not work well or caused side effects.
  5. You have never taken vedolizumab or similar integrin medicines.
  6. You have ulcerative colitis, not Crohn's disease.
Answer every question to see your result.

What does participation involve?

If you decide to join, you will be assigned to a treatment group by chance. You will receive either emvistegrast or a dummy medicine (placebo). You will need to attend regular clinic visits at the hospital so the medical team can monitor your health. These visits will involve health checks, blood and stool tests, and camera examinations of your bowel (endoscopies) to see if your gut lining is healing. The primary part of the study checks your progress at 12 weeks, with additional follow-up visits to ensure your safety. All trial medicines, clinic appointments, and tests are provided at no cost to you.

Potential risks and benefits

Taking part may help improve your ulcerative colitis symptoms and gut healing, and you will receive close, expert medical care throughout the trial. However, there is no guarantee that the treatment will help, and you might receive a placebo without any active medicine. Like any new drug, emvistegrast may cause side effects, which the study team will explain to you before you start. Your participation is entirely voluntary, and you are free to leave the trial at any point without it affecting your standard NHS care.

Locations (181)

  • Onyx Clinical Research (Clinic Location)
    Verified postcode
    Peoria, United States
  • Om Research LLC
    Verified postcode
    Camarillo, United States
  • VVCRD Research
    Verified postcode
    Garden Grove, United States
  • 310 Clinical Research
    Verified postcode
    Inglewood, United States
  • US San Diego Health System
    Verified postcode
    La Jolla, United States
  • Om Research LLC
    Verified postcode
    Lancaster, United States
  • UCSF Benioff Children's Hospital Oakland
    Verified postcode
    Oakland, United States
  • University Of California, Davis
    Verified postcode
    Sacramento, United States
  • SDG Clinical Research, LLC
    Verified postcode
    San Diego, United States
  • Acclaim Clinical Research
    Verified postcode
    San Diego, United States
  • Peak Gastroenterology Associates
    Verified postcode
    Colorado Springs, United States
  • Peak Gastroenterology Associates
    Verified postcode
    Colorado Springs, United States

Common questions

What is a placebo and why is it used?

A placebo looks just like the real medicine but contains no active ingredients. It is used so researchers can clearly tell whether any improvements or side effects are truly caused by the study drug.

Will I have to pay for the study treatment?

No. The trial medicine, tests, and doctor visits are provided free of charge, and you may also receive help to cover your travel costs.

Can I stay on my regular ulcerative colitis medicines?

Some medications may be allowed at steady doses, while others may need to be paused. The study doctor will review all your current treatments to make sure it is safe for you to take part.

How long will I be involved in the study?

The main goal of the study is to assess your response after 12 weeks of treatment, though the total time includes screening visits beforehand and safety checks afterwards.

What happens if my symptoms get worse during the trial?

Your health and comfort are the top priority. If your condition worsens, the medical team can provide rescue treatments or take you off the study to ensure you receive the best care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.